Although the ERBB2 status of mammary tumours in canines is not yet considered in veterinary medicine, it is essential to note that trastuzumab has been shown to significantly inhibit the proliferation of canine mammary carcinoma cell lines in vitro [195]. Here, ERBB2 is linked to breast carcinoma.